CD4 and AIDS: We aimed to compare the effect of DTG- or EFV-based regimens on early mortality rates, frequency of adverse events, CD4 changes from baseline, and treatment changes/discontinuation in patients with advanced AIDS (WHO classification stage 4 and baseline CD4 cell count below 50 cells/mm3).